key: cord-0752093-f57wdryd
authors: Chudasama, Y. V.; Zaccardi, F.; Gillies, C. L.; Razieh, C.; Yates, T.; Kloecker, D. E.; Rowlands, A. V.; Davies, M. J.; Islam, N.; Seidu, S.; Forouhi, N. G.; Khunti, K.
title: Patterns of Multimorbidity and Risk of Severe SARS-CoV-2 Infection: an observational study in the U.K.
date: 2020-10-23
journal: nan
DOI: 10.1101/2020.10.21.20216721
sha: ba33ef3237a82ad77693e7de5697a8d061aacf63
doc_id: 752093
cord_uid: f57wdryd

Background Pre-existing comorbidities have been linked to SARS-CoV-2 infection but evidence is sparse on the importance and pattern of multimorbidity (2 or more conditions) and severity of infection indicated by hospitalisation or mortality. We aimed to use a multimorbidity index developed specifically for COVID-19 to investigate the association between multimorbidity and risk of severe SARS-CoV-2 infection. Methods We used data from the UK Biobank linked to laboratory confirmed test results for SARS-CoV-2 infection and mortality data from Public Health England between March 16 and July 26, 2020. By reviewing the current literature on COVID-19 we derived a multimorbidity index including: 1) angina; 2) asthma; 3) atrial fibrillation; 4) cancer; 5) chronic kidney disease; 6) chronic obstructive pulmonary disease; 7) diabetes mellitus; 8) heart failure; 9) hypertension; 10) myocardial infarction; 11) peripheral vascular disease; 12) stroke. Adjusted logistic regression models were used to assess the association between multimorbidity and risk of severe SARS-CoV-2 infection (hospitalisation or death). Potential effect modifiers of the association were assessed: age, sex, ethnicity, deprivation, smoking status, body mass index, air pollution, 25-hydroxyvitamin D, cardiorespiratory fitness, high sensitivity C-reactive protein. Results Among 360,283 participants, the median age was 68 [range, 48-85] years, most were White (94.5%), and 1,706 had severe SARS-CoV-2 infection. The prevalence of multimorbidity was more than double in those with severe SARS-CoV-2 infection (25%) compared to those without (11%), and clusters of several multimorbidities were more common in those with severe SARS-CoV-2 infection. The most common clusters with severe SARS-CoV-2 infection were stroke with hypertension (79% of those with stroke had hypertension); diabetes and hypertension (72%); and chronic kidney disease and hypertension (68%). Multimorbidity was independently associated with a greater risk of severe SARS-CoV-2 infection (adjusted odds ratio 1.91 [95% confidence interval 1.70, 2.15] compared to no multimorbidity). The risk remained consistent across potential effect modifiers, except for greater risk among men. Conclusion The risk of severe SARS-CoV-2 infection is higher in individuals with multimorbidity, indicating the need to target research and resources in people with SARS-CoV-2 infection and multimorbidity.

The novel coronavirus SARS-CoV-2 has led to a global pandemic of a complex, pneumoniarelated illness . As of 29 th September 2020, there have been 33, 749, 599 confirmed cases of COVID-19 and 1,009,829 deaths reported worldwide.

[1] Many countries are still facing a devastating rise in the number of cases and deaths, whist some are facing a second wave such as France, Spain, UK, with significant impacts on their healthcare systems. The risk of SARS-CoV-2 infection is based on the person-to-person transmission rate at which the virus is circulating in the community. [2, 3] Yet, while some individuals recover from the SARS-CoV-2 infection, others develop severe illness which may require intensive care in hospital or result in mortality.

Several potential factors have been postulated or associated with the increased risk of transmission and development of severe SARS-CoV-2 infection, such as age, ethnicity, body mass index (BMI), smoking, deprivation, pre-existing comorbidities (particularly diabetes, hypertension and cardiovascular disease), cardiorespiratory fitness, 25- hydroxyvitamin D level, air pollution and inflammation. [4] However, individuals with preexisting health conditions have been found to have the highest risk of developing severe SARS-CoV-2 infection, as shown in a number of studies from early research based in Wuhan [5] to recent studies across the globe. [6] [7] [8] Nevertheless, the majority of research to date has focused on pre-existing single chronic conditions, [9] yet individuals often have multiple chronic conditions, known as multimorbidity. In view of the rapidly increasing prevalence of severe SARS-CoV-2 infection across the globe, clarifying the pattern and impact of multimorbidity (defined as 2 or more conditions) on the risk of severe SARS-CoV-2 infection has important clinical and public health implications which are not captured by a focus on single diseases. [10] There are a number of methods to define multimorbidity, which include both simple measures such as summing up the diseases and more complex measures using a weighted score such as the Charles Comorbidity Index. A previous study in UK Biobank examined the pattern of the most prevalent clusters of multimorbidity in those infected with SARS-CoV-2, using 36 different conditions to define multimorbidity, [11] though this masked the most relevant conditions related to SARS-CoV-2. [12] Moreover, three studies which assessed the risk of multimorbidity and COVID-19 had also used a broad range of conditions (ranging from 19 to 43 conditions). [13] [14] [15] In contrast, the available evidence indicates that certain health conditions are associated with a much greater risk of severe SARS-CoV-2 infection linked with hospitalisation or mortality. [5, 16] To help clarify the evidence, in this study we aimed to firstly develop a multimorbidity index of the most commonly reported chronic conditions from the current literature for severe SARS-CoV-2 infection. The index was then used to investigate the patterns and association between multimorbidity and risk of severe SARS-CoV-2 infection and we further tested whether this association was modified by other potential risk factors. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint SARS-CoV-2 laboratory confirmed test results and death data for all-cause mortality from Public Health England were linked to the UK Biobank database. [19] Data were available between March 16 and July 26, 2020, restricted to those tested in a hospital (pillar 1), since this can be regarded as a proxy for hospitalisations for severe cases of the disease as suggested by the linkage methodology. [19] Our analytical sample included study participants from England as testing was available and linked, we therefore excluded study members from Scotland and Wales, participants who had an outpatient test positive for COVID-19 (pillar 2) as the outcome for SARS-CoV-2 infection was uncertain (i.e. recovered, hospitalised at a later stage, or died), those who died before March 16, 2020, and those with missing data (Additional file: Figure S1 ).

To use prior evidence on comorbidities that cluster together and that may act in combination to affect the risk of COVID-19, we carried out a literature search to identify the most common pre-existing comorbidities in patients with severe SARS-CoV-2 infection (Additional file:

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint Table S1 ). The studies from the literature search were found to be very heterogeneous, therefore it was not possible to do a quantitative meta-analysis of pooled results. [5] [6] [7] [8] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] From a semi-quantitative perspective, we selected the most common conditions to create a multimorbidity index for severe COVID-19 including the following conditions: 1) angina; 2) asthma; 3) atrial fibrillation; 4) cancer; 5) chronic kidney disease (CKD); 6) chronic obstructive pulmonary disease (COPD); 7) diabetes mellitus; 8) heart failure; 9) hypertension; 10) myocardial infarction; 11) peripheral vascular disease; and 12) stroke.

Data on these comorbidities were available in UK Biobank together with the clinical marker of CKD, the estimated Glomerular Filtration Rate (eGFR) value less than 60 mL/min/1.73m 2 .

Those with two or more of these conditions clustering together were assigned as having multimorbidity and the remainder without multimorbidity.

The outcome was severe SARS-CoV-2 infection, defined as admission to hospital with a positive SARS-CoV-2 infection test result or death occurring within the study period of March 16 to July 26 July, 2020. The comparison group without severe SARS-CoV-2 infection included participants with negative test result for SARS-CoV-2 either in a hospital setting or as outpatient, or having not been tested. Participants who received a positive test outside of a hospital setting were excluded from this analysis, as their outcome was uncertain (i.e. recovered, hospitalised at a later stage, or died).

The association between multimorbidity and severe SARS-CoV-2 infection was assessed across levels of prespecified potential effect modifiers based on the literature, including: 1) age at test (grouped as <60 years or  60 years; 2) sex; 3) ethnicity (self-reported and grouped as white or non-white); 4) Townsend deprivation index (used to measure socioeconomic status, which combines census data on housing, employment, and social class based on the postal code of participants; a higher Townsend score equates to higher levels is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. 

We examined the baseline descriptive characteristics of the UK Biobank cohort among participants with and without severe SARS-CoV-2 infection. The age at the time of SARS-CoV-2 test was calculated using the baseline date and the test date. Continuous variables were presented as means and standard deviations, and the categorical variables presented as counts and percentages. Complete case framework was used for all analyses. A heat . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint map was created to illustrate the pattern of the most common clusters of multimorbidity by severe SARS-CoV-2 infection and the remaining cohort. The proportion and date of those with severe SARS-CoV-2 infection by multimorbidity was also illustrated to understand the pattern over the time of the pandemic.

The association between multimorbidity and severe SARS-CoV-2 infection was estimated using logistic regression models. The odds ratio (OR) and 95% confidence intervals (CI)

were reported comparing multimorbidity versus no multimorbidity (reference). Models were adjusted for age at test, sex, ethnicity, deprivation, smoking status, BMI, air pollution, serum 25-hydroxyvitamin D, cardiorespiratory fitness, serum C-reactive protein, season at blood draw [categorised by the months: spring (March, April, May), summer (June, July, August), autumn (September, October, November), and winter (December, January, February)], and regular intake of vitamin D supplement (yes or no). Stratified analyses were used for the ten potential effect modifiers, and we tested for interaction effects using a Likelihood ratio test and the related P-value.

In sensitivity analyses to assess the robustness of our results, we repeated the stratified analyses using 3 or more comorbid conditions. Moreover, we further stratified the analyses using four 25-hydroxyvitamin D levels (<25, 25-50, 50-75, >75 nmol/L) and also included a more recent testing phase for 25-hydroxyvitamin D levels; and we used the air pollution level markers NO2 and PM 2.5 at the last recorded measure. A P-value less than 0.05 was considered statistically significant. All analyses were performed in Stata version 16.0. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020.

In 360,283 UK Biobank participants, 1,706 (0.5%) had severe SARS-CoV-2 infection. The median [range] age was 68 [48-85] years and most participants were White (94.5%).

Compared with participants without severe SARS-CoV-2 infection, those with severe infection were older (≥ 60 years: 86% vs. 77%), mainly men (58% vs. 46%), more likely to live in deprived areas (60% vs. 50%), with higher mean BMI (28.6 kg/m 2 vs 27.4 kg/m 2 ), were current or previous smokers, had vitamin D deficiency (16% vs.12%), and more frequently reported a slow walking pace (17% vs. 7%); Table1.

The most prevalent pre-existing multimorbidity index conditions in those with severe SARS-CoV-2 infection were hypertension (39.6%), asthma (13.3%), diabetes (10.0%), cancer (9.9%), and angina (6.5%; Table 2 ). There was a higher prevalence of hypertension (39.6% vs. 25.3%) and diabetes (10% vs. 3.9%) in individuals with severe SARS-CoV-2 infection compared to those without. The prevalence of multimorbidity (2 or more conditions) was over double in those with severe SARS-CoV-2 infection (25.3%) compared to those without severe SARS-CoV-2 infection (11.6%; Table 2) , where the most common clusters were found in those with both stroke and hypertension (79% of those with stroke had hypertension), diabetes and hypertension (72% of those with diabetes), CKD and hypertension (68% of those with CKD), angina and hypertension (67% of those with angina; Figure 1 ). The trend of severe SARS-CoV-2 infection cases in this study peaked at the end of March and beginning of April 2020, and those with multimorbidity had a consistently higher proportion of cases during the period compared to those without multimorbidity; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint

The risk of severe SARS-CoV-2 infection increased with the number of pre-existing multimorbidity index conditions, illustrated by the higher odds ratios across the number of increasing conditions ( Table 3 . The odds ratios remained generally consistent with the overall associations when estimated across strata of effect modifiers (Figure 3) . The association was slightly stronger in men compared to women. It was also apparent that the risk differed across the most common clusters of multimorbidity ( In sensitivity analyses, the results were similar when examining the association between the multimorbidity index using 3 or more comorbid conditions and the risk of severe SARS-CoV-2 infection (Additional file: Table S2 ), however the interaction effect between men and women was non-significant. The results remained consistent over time, when assessing the 25OH-vitamin D levels at a later phase and when using the last recorded air pollution NO2 and PM 2.5 levels (Additional file: Table S3 ).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint

Our review of the published literature indicated that the most commonly reported chronic conditions for severe SARS-CoV-2 infection were cardiometabolic diseases. Data from the UK Biobank study using the multimorbidity index conditions showed that 25% of those with severe SARS-CoV-2 infection had multimorbidity (2 or more conditions). The major clusters were stroke and hypertension; diabetes and hypertension; CKD and hypertension; and angina and hypertension. Over the study period the risk of severe SARS-CoV-2 infection was consistently higher for those with multimorbidity compared to those without multimorbidity. Moreover, our results highlight that the greater risk of severe infection was consistent with that of the overall effect of multimorbidity when stratifying by the potential effect modifiers. The only exception was when stratifying by sex, with a greater magnitude of association between multimorbidity and severe infection in men compared with women.

To our knowledge, this is the first study to develop a multimorbidity index using the most common conditions from the current COVID-19 literature. There have been three previously published studies that assessed the association between multimorbidity and the risk of SARS-CoV-2 infection. The first was an online questionnaire study by 26 hospitals across Italy undertaken in March 9 to April 9, 2020, with a total of 1,591 participants admitted with SARS-CoV-2 infection (188 non-survivors, 1,403 survivors). [14] The study used the Charles Comorbidity Index (CCI) which takes into account age and 19 conditions in an algorithm to predict 10-year mortality. The authors found an exponential increase in the odds by each point of the CCI score. [14] Our multimorbidity index found similar results since the risk of severe SARS-CoV-2 infection increased with the number of pre-existing multimorbidity index conditions. Two studies were based in UK Biobank, however the study design and outcomes is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint [15] the outcome was based on testing positive in any setting (hospital or outpatient, pillar 1 and 2), which may introduce testing bias within UK Biobank. A recent article illustrated how the same dataset can produce apparently paradoxical findings for the same outcome. [34] For this reason, our study examined harder outcomes for those with severe SARS-CoV-2 infection; hospitalisation or death during the pandemic compared to the remaining cohort. Moreover, the three studies to date have only presented the number of conditions but have not examined the patterns of multimorbidity, i.e. the type of the two most common co-occurring conditions found in those with severe SARS-CoV-2 infection, nor the rate of severe infection or mortality in people with multimorbidity over the period of the pandemic.

Hypertension was found to be the most prevalent condition (40%) in those with severe SARS-CoV-2 infection, as in a number of previously published studies. Yet, when examined by clusters, we found that hypertension mainly co-existed with other conditions (i.e. diabetes, stroke, CKD). Thus, certain clusters of the multimorbidity index are more frequent than other clusters. For this reason, we believe that the classification of those with preexisting multimorbidity index conditions is crucial to provide prognostic information to tailor effective treatment and prevent severe outcomes in common chronic conditions. Further research is required to understand the biological mechanisms involved between these . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. A key strength of this study is the overall large sample size which allowed us to investigate whether the associations were heterogeneous across clinically relevant effect modifiers. We employed a comprehensive list of effect modifiers, extending past research and enabling a greater understanding of the association between multimorbidity and severe SARS-CoV-2 infection. Moreover, we performed a literature review to derive an evidence based COVID-19 relevant multimorbidity index which can be applied to other populations. [5] [6] [7] [8] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] This study has some limitations. Issues of the low response rate (~5%) and selection bias, such as slightly higher representation of participants from affluent groups may suggest that the UK Biobank sample is not well representative of the UK population, and have been discussed previously. [36] However, participants may not need to be representative of the target populations when estimating relative risks, as empirically demonstrated for UK Biobank. [37] The characteristics we examined were recorded at recruitment, representing data collected in the past at study baseline, but we conducted additional sensitivity analyses using the follow-up data for 25-hydroxyvitamin D levels and the last recorded air pollution (NO2) data, showing consistent results over time. The data on multimorbidity were appraised . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint only at baseline but there may have been a change in the number of multimorbidity index conditions since recruitment which were not accounted for and may lead to under or overestimation of effect. We were unable to assess the severity of disease conditions but our new multimorbidity index definition included conditions that were most relevant to COVID-19. Another limitation is the lack of detail of clinical severity of those with severe SARS-CoV-2 infection: while we have accounted for hospitalisation or death during the pandemic, further details of adverse COVID-19 outcomes such as length of hospital stay, intensive care admission, or mechanical ventilation, could provide further information. Ten potential effect modifiers were selected, [4] although there are other factors which could possibly modify the association between multimorbidity and risk of severe SARS-CoV-2 infection but were unaccounted for, such as household size, occupation, and understanding and behaviour for social distancing, shielding, wearing facemasks and hand hygiene.

Finally, this was an observational study, which limits our ability to establish causality.

In conclusion, our results indicate that multimorbidity is associated with a significantly higher risk of severe SARS-CoV-2 infection across multiple patient characteristics. Stratifying the risk according to the presence of multimorbidity, and reinforcing initiatives and resources to reduce the risk in this vulnerable group of individuals should be considered as priorities in the current coronavirus pandemic. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint Author contributions: is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint Table 2 . Multimorbidity index conditions among participants in the UK Biobank Study a Severe SARS-CoV-2 infection included those with a positive test result for SARS-CoV-2 with hospitalisation, or those who died during the study period (16 March to 26 July, 2020). b Those without severe SARS-CoV-2 infection included those who had not been tested, or who had tested negative for SARS-CoV-2. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint Reference is the group without multimorbidity (<2 conditions).

OR=odds ratio; CI=confidence interval; NO2=nitrogen dioxide.

Multimorbidity index conditions include: angina, asthma, atrial fibrillation, cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, heart failure, hypertension, myocardial infarction, peripheral vascular disease, and stroke.

Models adjusted for age at test, sex, ethnicity, deprivation, smoking status, body mass index, air pollution, 25-hydroxyvitamin D, cardiorespiratory fitness, C-reactive protein, season at blood draw, and regular intake of Vitamin D supplement. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 23, 2020. ; https://doi.org/10.1101/2020.10.21.20216721 doi: medRxiv preprint

Coronavirus Update (Live)

Evidence for Limited Early Spread of COVID-19 Within the United States

Defining the Epidemiology of Covid-19 -Studies Needed

South Asian Health Foundation: COVID-19 in Black, Asian and Minority Ethnic populations: An evidence review and recommendations from the South Asian Health Foundation

Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. The Journals of Gerontology: Series A 2020. 10. Multimorbidity: a priority for global health research. Available at

Multimorbidity and SARS-CoV-2 infection in UK Biobank | Elsevier Enhanced Reader

Response to 'Multimorbidity and SARS-CoV-2 infection in UK biobank'. Diabetes & metabolic syndrome

COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank participants

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort

Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis

Protocol for a large-scale prospective epidemiological resource

Available at

Dynamic linkage of COVID-19 test results between Public Health England's Second Generation Surveillance System and UK Biobank

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: A Nationwide Case-Control Study

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan | Elsevier Enhanced Reader

The Permanente Medical Group KPNC, Oakland: Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California

A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients

Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis

Clinical Course and Outcomes of Critically Ill Patients With SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(outdoor)-air-quality-and-health

Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality: A UK Biobank observational study

Markers of Inflammation and Cardiovascular Disease

Framework to aid analysis and interpretation of ongoing COVID-19 research

Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals

The UK Biobank and selection bias

Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant metaanalysis

Reference is those without the stated two co-occurring conditions (i.e. with asthma and hypertension vs. without asthma and hypertension

OR=odds ratio; CI=confidence interval; CKD=chronic kidney disease

Models adjusted for age at test, sex, ethnicity, deprivation, smoking status, body mass index, air pollution, 25-hydroxyvitamin D, cardiorespiratory fitness, C-reactive protein, season at blood draw, and regular intake of vitamin D supplement

Multimorbidity index conditions include: angina, asthma, atrial fibrillation, cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, heart failure, hypertension, myocardial infarction, peripheral vascular disease, and stroke.